Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection

ConclusionsTimely control of infection, assessment of bleeding and thrombotic risks, and selection of appropriate anticoagulation treatment strategies should be made in older NVAF patients who develop pulmonary infection.Clinical Trials RegistrationChinese Clinical Trial Registry Number ChiCTR2000033144.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research